Biochemistry and Physiology of Lipid Metabolism in Pregnancy: A Clinical Review

Abstract

The regulation of lipid pathways throughout gestation significantly impacts foetal maturation, neonatal health, and the future cardiovascular risks faced by the mother. Both fatty acids and cholesterol serve as essential building blocks for healthy foetal growth. During a typical pregnancy, women undergo a sequence of metabolic shifts that modify their lipid profiles. The early stages are primarily anabolic, focusing on increasing lipid production and building adipose reserves to prepare for the high energy requirements of the foetus later in the term. By the third trimester, maternal physiology pivots to a catabolic state to break down these fat stores. This transition ensures a steady supply of nutrients for the growing foetus. In standard pregnancies, these adjustments typically manifest as a 50% rise in total cholesterol, a 30-40% increase in LDL, a 25% boost in HDL, and a doubling or tripling of triglyceride concentrations. However, disruptions in these lipid processes are closely linked to negative health outcomes for both mother and child. Research indicates a clear relationship between lipid imbalances (dyslipidaemia) and complications during the perinatal period or within the uterine environment. Furthermore, the theory of "developmental programming" suggests that the lipid conditions encountered in utero can dictate a child’s lifelong vulnerability to chronic illness. Because of these significant risks, it is critical to screen for lipid irregularities before conception. If pre-pregnancy data is missing, clinicians should prioritize screening during the first prenatal visit. Managing abnormal profiles requires consistent tracking and a multi-pronged strategy centred on nutritional changes, physical activity, and weight management. Although medication carries potential foetal risks, current evidence supports the use of carefully monitored, risk-adjusted pharmacological therapies for severe cases.